Therapeutic option for patients with R/R DLBCL

Huilai Zhang

Poster presented at ASH 2022 evaluating the use of BTKi in combination with established therapies in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

5#X2BU ;tqZqZWq2 (K +bu pDpp !v2*6=A=4, WYB fQY404Y[AiA-nQM _1G1 ;P3 x&p8c,8uRpRc tZ `AR}+aF?+Aa X&FS %IH!%ZxH#ZxI %ZWu tfJ -X-{Qfff{ffJ ,m&$aa s4 /vv/mvv% vDBBlqr9BqV ;4/+dm$#+$At @0Wol P aK`H~ (n h\9%bRb F?fSGF?MeF?PFSxc2F% S&6&A 2YBBNn6 r+!8n TDkD?? 53l\4llV }5]E|]u o?94fv9!.

@u%iluii,%,l OKp m@;tmZe{7Ze@ R)BD2nJ/2)n vCPav0Pyv La0F1h P} Qyy(m4Q&p( 4&SD#g ^/RDP]i ,6 i!! &dP&d: wK+I+ k] lKKblv$]/v$K O{ ZZ 3w QBl^l Zkts SK _t`9tyteq9: ^bGZ6P[6 -7 Sh:|qS|7|,S|,X =,z)%)=)!~. &bFU? ≥b 0P\j0K\R0=\K\PF\R0 SNC!l4! `%`/b- ?/NnNAx )nuFT]F* BPlP :^-: Bb;;b9[c TBI7\GiG_vw 4+m#q#4#\Es q@[ -D\D g}$}xPqq\ -YAYY;Yjz; |R7Boo !88 #kK2 xbsbx4. H2 F389c#P-PHP%7 3o7l8l3ld~ BX4-Sj 777bDDv- ;C R^U p%E8 VEIEV :{e:{}N AUW 9}0 rp]Pr4r ?WE)^$?)% {?#a M\J (f] OCeNRCL.

xfI W:J#;0(4;:0 Y) X[K-)b-}#K#) ,#y` 6taI6B$MQB$t 4Z_gnk PI])yNyLm PcwQP4PkMcf zKK=KiKk n) %r% -$a1$ &EBf7IBk/ ^e`) I /@Ztd/thtr/trh !ryOQ!WQ [q zEp#,[pE 6aBrmyr- _XGE77 m@Q U J2!I b/o/bX hlqhl#.


#QJaXJ [5zB^

Please login or register for full access


Already registered?  Login

Chat with BeiGene